Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASH 2018 /
Initial report of the Beat AML umbrella study for previously untreated AML

1st - 4th Dec 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 02.12.18
Views: 138

Dr Amy Burd - Leukemia and Lymphoma Society, White Plains, USA

Dr Amy Burd gives a press conference at ASH 2018 about the Beat AML study.

Dr Burd describes that the study was designed to assess whether a trial could use gene profiling to assign patients to subtype-specific therapies, and to delineate the role of new therapies in the first-line treatment of AML, with the goal of improving outcomes in older patients through the use of mechanism based novel therapies.

Read the article about this work here.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation